Download PDF
Thromb Haemost 1999; 82(S 01): 44-52
DOI: 10.1055/s-0037-1615552
Commentaries
Schattauer GmbH

Angiogenesis in Ischemic Disease

Hugo H. Marti
1   Max Planck Institute for Physiological and Clinical Research, Department of Molecular Cell Biology, Bad Nauheim, Germany
,
Werner Risau   †
1   Max Planck Institute for Physiological and Clinical Research, Department of Molecular Cell Biology, Bad Nauheim, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

Angiogenic growth factors and their endothelial receptors function as major regulators of blood vessel formation. The VEGF/VEGFR and the Angiopoietin/Tie2 receptor systems represent key signal transduction pathways involved in the regulation of embryonic vascular development. Inactivation of any of the genes encoding these molecules results in defective vascular development and lethality between embryonic day 8.5 and 12.5. In addition, VEGF and its receptors are also critically involved in the regulation of pathological blood vessel growth in the adult during various angiogenesis-dependent diseases that are associated with tissue hypoxia, such as solid tumor growth and ischemic diseases. It is now well established that therapeutic angiogenesis can be achieved in animal models of hind limb and myocardial ischemia by exogenously adding VEGF and/or other angiogenic growth factors. Available clinical data from human trials also suggests that patients with severe cardiovascular diseases could potentially benefit from such therapies. However, much more work needs to be done to compare the potency of different angiogenic factors or the combination thereof, as well as the best way of delivery, either as recombinant proteins, as naked DNA or via adenoviral vectors. Nevertheless, the therapeutic efficacy of simply injecting naked plasmid DNA or proteins into ischemic tissue to deliver secreted angiogenic factors is an encouraging finding. Time will show whether the adverse side effects of therapeutic angiogenesis, mainly vascular permeability and edema formation, can be minimized and angiogenic factors can be used as an effective therapy in patients for the treatment of ischemic diseases such as arterial occlusive disease, myocardial infarction, and, eventually, also stroke.

Key words

Ischemia - therapeutic angiogenesis - VEGF - angiopoietin - hypoxia - HIF-1 - stroke - myocardial infarction

† In Memoriam Prof. Werner Risau, December 18, 1953 – December 13, 1998


 

  • References

  • 1 Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995; 11: 73-91.
    CrossrefPubMedGoogle Scholar
  • 2 Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
    CrossrefPubMedGoogle Scholar
  • 3 Buschmann I, Schaper W. Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News Physiol Sci 1999; 14: 121-5.
    PubMedGoogle Scholar
  • 4 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
    CrossrefPubMedGoogle Scholar
  • 5 Yancopoulos GD, Klagsbrun M, Folkman J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998; 93: 661-4.
    PubMedGoogle Scholar
  • 6 Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specifc receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13: 1055-66.
    CrossrefPubMedGoogle Scholar
  • 7 Risau W. Angiogenic factors. Prog Growth Factor Res 1990; 2: 71-9.
    CrossrefPubMedGoogle Scholar
  • 8 Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997; 3: 158-64.
    CrossrefPubMedGoogle Scholar
  • 9 Risau W. What, if anything is an angiogenic factor?. Cancer Metast Rev 1996; 15: 149-51.
    CrossrefPubMedGoogle Scholar
  • 10 Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
    CrossrefPubMedGoogle Scholar
  • 11 Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-12.
    CrossrefPubMedGoogle Scholar
  • 12 Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996; 93: 2576-81.
    CrossrefPubMedGoogle Scholar
  • 13 Grimmond S, Lagercrantz J, Drinkwater C, Silins G, Townson S, Pollock P, Gotley D, Carson E, Rakar S, Nordenskojld M, Ward L, Hayward N, Weber G. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res 1996; 6: 124-31.
    CrossrefPubMedGoogle Scholar
  • 14 Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Sakesla O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290-8.
    PubMedGoogle Scholar
  • 15 Lee J, Gray A, Yuan J, Luoh S-M, Avraham H, Wood WI. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 1996; 93: 1988-92.
    CrossrefPubMedGoogle Scholar
  • 16 Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA 1996; 93: 11675-80.
    CrossrefPubMedGoogle Scholar
  • 17 Yamada Y, Nezu J, Shimane M, Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGD-D. Genomics 1997; 42: 483-8.
    CrossrefPubMedGoogle Scholar
  • 18 Lyttle DJ, Fraser KM, Fleming SB, Mercer AA, Robinson AJ. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 1994; 68: 84-92.
    PubMedGoogle Scholar
  • 19 Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, Rziha H-J, Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinase. EMBO J 1999; 18: 363-74.
    CrossrefPubMedGoogle Scholar
  • 20 Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998; 273: 31273-82.
    CrossrefPubMedGoogle Scholar
  • 21 Wise LM, Veikkola T, Mercer AA, Savory LJ, Fleming SB, Caesar C, Vitali A, Makinen T, Alitalo K, Stacker SA. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci USA 1999; 96: 3071-6.
    CrossrefPubMedGoogle Scholar
  • 22 Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991; 88: 9267-71.
    CrossrefPubMedGoogle Scholar
  • 23 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
    CrossrefPubMedGoogle Scholar
  • 24 Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G. VEGF145, a secreted vascular endothelial growth factor iso- form that binds to extracellular matrix. J Biol Chem 1997; 272: 7151-8.
    CrossrefPubMedGoogle Scholar
  • 25 Neufeld G, Cohen T. Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
    PubMedGoogle Scholar
  • 26 Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard JC, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D'Amore PA, Shima DT. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999; 5: 495-502.
    CrossrefPubMedGoogle Scholar
  • 27 Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 1998; 95: 15809-14.
    CrossrefPubMedGoogle Scholar
  • 28 Clauss M. Functions of the VEGF receptor-1 (Flt-1) in the vasculature. Trends Cardiovasc Med 1998; 8: 241-5.
    CrossrefPubMedGoogle Scholar
  • 29 Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-45.
    CrossrefPubMedGoogle Scholar
  • 30 Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-9.
    CrossrefPubMedGoogle Scholar
  • 31 Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-42.
    CrossrefPubMedGoogle Scholar
  • 32 Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in flk-1-deficient mice. Nature 1995; 376: 62-6.
    CrossrefPubMedGoogle Scholar
  • 33 Fong G-H, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
    CrossrefPubMedGoogle Scholar
  • 34 Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-54.
    PubMedGoogle Scholar
  • 35 Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U. Vascular endothelial growth-factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-14.
    CrossrefPubMedGoogle Scholar
  • 36 Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997; 16: 3898-911.
    CrossrefPubMedGoogle Scholar
  • 37 Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgernic mice. Science 1997; 276: 1423-5.
    CrossrefPubMedGoogle Scholar
  • 38 Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, Principe N, Kearney M, Hu J-S, Isner JM. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998; 153: 381-94.
    CrossrefPubMedGoogle Scholar
  • 39 Enholm B, Jussila L, Karkkainen M, Alitalo K. Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells. Trends Cardiovasc Med 1998; 8: 292-7.
    CrossrefPubMedGoogle Scholar
  • 40 Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi J-H, Claesson-Welsh L, Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998; 95: 14389-94.
    CrossrefPubMedGoogle Scholar
  • 41 Dumont DJ, Jussila L, Taipale L, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282: 946-9.
    CrossrefPubMedGoogle Scholar
  • 42 Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95: 548-53.
    CrossrefPubMedGoogle Scholar
  • 43 Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radzie-jewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
    CrossrefPubMedGoogle Scholar
  • 44 Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, Huang T, Papadopoulos N, Maisonpierre PC, Davis S, Yancopoulos GD. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999; 96: 1904-9.
    CrossrefPubMedGoogle Scholar
  • 45 Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-9.
    CrossrefPubMedGoogle Scholar
  • 46 Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995; 129: 895-8.
    CrossrefPubMedGoogle Scholar
  • 47 Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Angio-poietin-1 induces sprouting angiogenesis in vitro. Curr Biol 1998; 8: 529-32.
    CrossrefPubMedGoogle Scholar
  • 48 Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase tie2. J Biol Chem 1998; 273: 18514-21.
    CrossrefPubMedGoogle Scholar
  • 49 Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-71.
    CrossrefPubMedGoogle Scholar
  • 50 Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83: 233-40.
    CrossrefPubMedGoogle Scholar
  • 51 Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. nature 1995; 376: 70-4.
    CrossrefPubMedGoogle Scholar
  • 52 Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the tie2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80.
    CrossrefPubMedGoogle Scholar
  • 53 Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 336-40.
    CrossrefPubMedGoogle Scholar
  • 54 Alon T, Hemo I, Itin A, Peer J, STone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-8.
    CrossrefPubMedGoogle Scholar
  • 55 Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-8.
    PubMedGoogle Scholar
  • 56 Gerber H-P, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313-6.
    CrossrefPubMedGoogle Scholar
  • 57 Meeson AP, Argilla M, Ko K, Witte L, Lang RA. VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development 1999; 126: 1407-15.
    PubMedGoogle Scholar
  • 58 Gerber H-P, Hillan KJ, Ryan AM, Kowalski J, Keller G-A, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 1999; 126: 1149-59.
    PubMedGoogle Scholar
  • 59 Shweiki D, Itin A, Soffer D, Keshet E. Vasculer endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
    CrossrefPubMedGoogle Scholar
  • 60 Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
    CrossrefPubMedGoogle Scholar
  • 61 Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
    CrossrefPubMedGoogle Scholar
  • 62 Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-9.
    CrossrefPubMedGoogle Scholar
  • 63 Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM. Dominant-negative inhibition of flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615-20.
    PubMedGoogle Scholar
  • 64 Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis?. Cell 1996; 87: 1153-5.
    CrossrefPubMedGoogle Scholar
  • 65 Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999; 274: 15732-9.
    CrossrefPubMedGoogle Scholar
  • 66 Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 1998; 177: 439-52.
    CrossrefPubMedGoogle Scholar
  • 67 Peters KG. Vascular endothelial growth factor and the angiopoietins. Working together to build a better blood vessel. Circ Res 1998; 83: 342-3.
    CrossrefPubMedGoogle Scholar
  • 68 Harik SI, Hritz MA, LaManna JC. Hypoxia-induced brain angiogenesis in the adult rat. J Physiol (London) 1995; 485: 525-30.
    CrossrefPubMedGoogle Scholar
  • 69 Boero JA, Ascher J, Arregui A, Rovainen C, Woolsey TA. Increased brain capillaries in chronic hypoxia. J Appl Physiol 1999; 86: 1211-9.
    CrossrefPubMedGoogle Scholar
  • 70 Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke 1996; 27: 1865-72.
    CrossrefPubMedGoogle Scholar
  • 71 Hayashi T, Abe K, Suzuki H, Itoyama Y. Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 1997; 28: 2039-44.
    CrossrefPubMedGoogle Scholar
  • 72 Cobbs CS, Chen J, Greenberg DA, Graham SH. Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat. Neurosci Lett 1998; 249: 79-82.
    CrossrefPubMedGoogle Scholar
  • 73 Lennmyr F, Ata KA, Funa K, Olsson Y, TerEnt A. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flt-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J Neuropathol Exp Neurol 1998; 57: 874-82.
    CrossrefPubMedGoogle Scholar
  • 74 Lee M-Y, Ju W-K, Cha J-H, Son BC, Chun M-H, Kang JK, Park CK. Expression of vascular endothelial growth factor mRNA following transient forebrain ischemia in rats. Neurosci Lett 1999; 265: 107-10.
    CrossrefPubMedGoogle Scholar
  • 75 Plate KH, Beck H, Danner S, Allegrini PR, Wiessner C. Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct. J Neuropathol Exp Neurol 1999; 58: 654-66.
    CrossrefPubMedGoogle Scholar
  • 76 Ijichi A, Sakuma S, Tofilon PJ. Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures. Glia 1995; 14: 87-93.
    CrossrefPubMedGoogle Scholar
  • 77 Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666-76.
    CrossrefPubMedGoogle Scholar
  • 78 Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NPH, Risau W, Ullrich A. High affinity VEGF binding and developmental suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-46.
    CrossrefPubMedGoogle Scholar
  • 79 Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995; 204: 228-39.
    CrossrefPubMedGoogle Scholar
  • 80 Yang XJ, Cepko CL. Flk-1, a receptor for vascular endothelial growth-factor (VEGF), is expressed by retinal progenitor cells. J Neurosci 1996; 16: 6089-99.
    CrossrefPubMedGoogle Scholar
  • 81 Rosenstein JM, Mani N, Silverman WF, Krum JM. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 7086-91.
    CrossrefPubMedGoogle Scholar
  • 82 Krum JM, Rosenstein JM. VEGF mRNA and its receptor flt-1 are expressed in reactive astrocytes following neural grafting and tumor cell implantation in the adult CNS. Exp Neurol 1998; 154: 57-65.
    CrossrefPubMedGoogle Scholar
  • 83 Silverman WF, Krum JM, Mani N, Rosenstein JM. Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures. Neuroscience 1999; 90: 1529-41.
    CrossrefPubMedGoogle Scholar
  • 84 Hayashi T, Abe K, Itoyama Y. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab 1998; 18: 887-95.
    CrossrefPubMedGoogle Scholar
  • 85 Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Up-regulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 1994; 28: 1176-9.
    CrossrefPubMedGoogle Scholar
  • 86 Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996; 270: H1803-11.
    PubMedGoogle Scholar
  • 87 Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor (VEGF) in C6 glioma cells. J Biol Chem 1995; 270: 19761-6.
    CrossrefPubMedGoogle Scholar
  • 88 Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ. Regulation of angiogenic growth factor expression by hypoxia, transition metals and chelating agents. Am J Physiol 1995; 268: C1362-8.
    CrossrefPubMedGoogle Scholar
  • 89 Kuo N-T, Benhayon D, Przybylski RJ, Martin RJ, LaManna JC. Prolonged hypoxia increases vascular endothelial growth factor mRNA and protein in adult mouse brain. J Appl Physiol 1999; 86: 260-4.
    CrossrefPubMedGoogle Scholar
  • 90 Forsythe JA, Jiang B-H, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
    CrossrefPubMedGoogle Scholar
  • 91 Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997; 378: 609-16.
    PubMedGoogle Scholar
  • 92 Wenger RH, Rolfs A, Marti HH, Guenet J-L, Gassmann M. Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxia-inducible factor-1. Biochem Biophys Res Commun 1996; 223: 54-9.
    CrossrefPubMedGoogle Scholar
  • 93 Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997; 386: 403-7.
    CrossrefPubMedGoogle Scholar
  • 94 Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1a. Genes Dev 1998; 12: 149-62.
    CrossrefPubMedGoogle Scholar
  • 95 Ryan HE, Lo J, Johnson RS. HIF-1 a is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17: 3005-15.
    CrossrefPubMedGoogle Scholar
  • 96 Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1a-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Develop Biol 1999; 209: 254-67.
    CrossrefPubMedGoogle Scholar
  • 97 Tian H, McKnight SL, Russell DW. Endothelial pas domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72-82.
    CrossrefPubMedGoogle Scholar
  • 98 Flamme I, Frohlich T, von Reutern M, Kappel A, Damert A, Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 and developmentally expressed in blood vessels. Mech Develop 1997; 63: 51-60.
    CrossrefPubMedGoogle Scholar
  • 99 Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1a regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94: 4273-8.
    CrossrefPubMedGoogle Scholar
  • 100 Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu Y-Z, Pray-Grant M, Perdew GH, Bradfield CA. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 1997; 272: 8581-93.
    CrossrefPubMedGoogle Scholar
  • 101 Kappel A, Ronicke V, Damert A, Flamme I, Risau W, Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999; 93: 4284-92.
    PubMedGoogle Scholar
  • 102 Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 1998; 12: 3320-4.
    CrossrefPubMedGoogle Scholar
  • 103 Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third a-class hypoxia inducible factor subunit, HIF3a. Gene Expression 1998; 7: 205-13.
    PubMedGoogle Scholar
  • 104 Dibbens JA, Miller DL, Damert A, Risau W, Vadas MA, Goodall GJ. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell 1999; 10: 907-10.
    CrossrefPubMedGoogle Scholar
  • 105 Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273: 6417-23.
    CrossrefPubMedGoogle Scholar
  • 106 Shih S-C, Claffey KP. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleo-protein L. J Biol Chem 1999; 274: 1359-65.
    CrossrefPubMedGoogle Scholar
  • 107 Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia. Mol Cell Biol 1998; 18: 3112-9.
    CrossrefPubMedGoogle Scholar
  • 108 Miller DL, Dibbens JA, Damert A, Risau W, Vadas MA, Goodall GJ. The vascular endothelial growth factor mRNA contains an internal ribosome entry site. FEBS Lett 1998; 434: 417-20.
    CrossrefPubMedGoogle Scholar
  • 109 Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995; 15: 5363-8.
    CrossrefPubMedGoogle Scholar
  • 110 Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 m-RNA regulation by serum growth factors oncoproteins and hypoxia. Oncogene 1997; 14: 2475-83.
    CrossrefPubMedGoogle Scholar
  • 111 Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83: 852-9.
    CrossrefPubMedGoogle Scholar
  • 112 Hockel M, Schlenger K, Doctrow S, Kissel T, Vaupel P. Therapeutic angiogenesis. Arch Surg 1993; 128: 423-9.
    CrossrefPubMedGoogle Scholar
  • 113 Takeshita S, Zheng LP, Brogi E, Kearney M, Pu L-Q, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662-70.
    CrossrefPubMedGoogle Scholar
  • 114 Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994; 89: 2183-9.
    CrossrefPubMedGoogle Scholar
  • 115 Pearlman JD, Hibberd MG, Chuang ML, Harada K, Lopez JJ, Gladstone SR, Friedman M, Sellke FW, Simons M. Magnetic resonance mapping demonstrates benefits of VEGF induced myocardial angiogenesis. Nat Med 1995; 1: 1085-9.
    CrossrefPubMedGoogle Scholar
  • 116 Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, Pearlman JD, Edelman ER, Sellke FW, Simons M. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996; 270: H1791-802.
    PubMedGoogle Scholar
  • 117 Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, Horowitz JR, Symes JF, Isner JM. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-90.
    CrossrefPubMedGoogle Scholar
  • 118 Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, Bauters C, Symes JF, Ferrara N, Isner JM. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 1996; 227: 628-35.
    CrossrefPubMedGoogle Scholar
  • 119 Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosen-field K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-4.
    CrossrefPubMedGoogle Scholar
  • 120 Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-23.
    CrossrefPubMedGoogle Scholar
  • 121 Rivard A, Isner JM. Angiogenesis and vasculogenesis in treatment of cardiovascular disease. Molecular Medicine 1998; 4: 429-40.
    PubMedGoogle Scholar
  • 122 Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645-50.
    CrossrefPubMedGoogle Scholar
  • 123 Shyu K-G, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998; 98: 2081-7.
    CrossrefPubMedGoogle Scholar
  • 124 Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998; 115: 168-76.
    CrossrefPubMedGoogle Scholar
  • 125 Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, Ferris B, Sanborn T, Isom OW, Crystal RG, Rosengart TK. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998; 27: 699-709.
    CrossrefPubMedGoogle Scholar